Latest / The Well-Built Life / Pioneering Pharmaceutical Innovation: Lloyd J. Old’s Journey
Transcript
- 0:00Speaker 1: Hey everyone, welcome back to The Well-Built Life. I am
- 0:03Speaker 1: Rachel Caldwell, alongside Thomas Bennett, and we are so glad
- 0:07Speaker 1: you are tuning in. We are here to cut through
- 0:10Speaker 1: the noise, skip the intense jargon and extreme rules, and
- 0:14Speaker 1: share simple practical habits that help you feel stronger, healthier,
- 0:18Speaker 1: and more balanced every single day. Grab a drink, get comfortable,
- 0:22Speaker 1: and let's dive in. Lloyd J. Old's career arc is
- 0:26Speaker 1: a fascinating tale of innovation and adaptation. particularly his move
- 0:31Speaker 1: from rheumatology to translational medicine. Let's dive into how his
- 0:35Speaker 1: expertise and vision transformed into groundbreaking initiatives like the New
- 0:40Speaker 1: Indications Discovery Unit, NICD at Novartis.
- 0:45Speaker 2: Exactly. It's intriguing how his dual background in clinical medicine
- 0:49Speaker 2: and research laid a solid foundation for such a pivot.
- 0:53Speaker 2: In the 1980s and 1990s, Old's rigorous academic journey at
- 0:58Speaker 2: the MD-PhD program at Brigham Women's Hospital must have been
- 1:02Speaker 2: instrumental in shaping his understanding of both the clinical and
- 1:06Speaker 2: research sides of medicine.
- 1:07Speaker 1: Right, and that's the crucial nuance here. He had the
- 1:11Speaker 1: technical know-how and scientific rigor to navigate the complex landscape
- 1:16Speaker 1: of translational medicine. His initial work focused on adhesion molecules
- 1:21Speaker 1: within the immune system during those formative years. which likely
- 1:25Speaker 1: honed his precision in biological and molecular contexts.
- 1:30Speaker 2: Wait, but how does that actually play out in practice?
- 1:33Speaker 2: Adhesion molecules sound a bit abstract. Can you give us
- 1:36Speaker 2: a concrete example of how this foundational research translated into
- 1:40Speaker 2: practical applications?
- 1:42Speaker 1: Sure. That transition from abstract to application is where Old's
- 1:46Speaker 1: expertise truly shines. Adhesion molecules are crucial in understanding cell
- 1:51Speaker 1: interactions and movement, which are pivotal in in areas like
- 1:56Speaker 1: cancer immunotherapy and autoimmune diseases. By grasping these mechanisms, Old
- 2:01Speaker 1: was positioned to develop new therapeutic strategies that can modulate
- 2:06Speaker 1: immune responses, a key area in translational medicine.
- 2:09Speaker 2: That's wild when you look at the raw numbers. And
- 2:12Speaker 2: from there, Old's shift to rheumatology for almost a decade
- 2:17Speaker 2: must have given him a deep understanding of patient needs.
- 2:20Speaker 2: How did his experience in treating rheumatological conditions impact his
- 2:24Speaker 2: approach to translational medicine?
- 2:26Speaker 1: His decade as a rheumatologist wasn't just about treating patients.
- 2:30Speaker 1: It was about seeing firsthand the limitations of current treatments.
- 2:35Speaker 1: This perspective was invaluable when he joined Novartis, bringing a
- 2:39Speaker 1: patient-centric lens to drug discovery and development. It was this
- 2:43Speaker 1: pragmatic approach that led him to establish the NICD, A
- 2:48Speaker 1: unit dedicated to discovering new indications for existing drugs and
- 2:53Speaker 1: identifying unmet medical needs.
- 2:56Speaker 2: Exactly. And the NICD's focus on unmet medical needs like
- 3:00Speaker 2: sarcopenia and geriatric diseases underscores the breadth of old's vision.
- 3:05Speaker 2: What does establishing such a unit look like in terms
- 3:07Speaker 2: of practical action? I mean, what kind of research and
- 3:11Speaker 2: development processes are involved in this new approach?
- 3:14Speaker 1: The process is multifaceted. The NICD employs a combination of
- 3:18Speaker 1: preclinical testing, clinical trials, and multidisciplinary research teams to tackle
- 3:24Speaker 1: a wide range of indications. For instance, it might involve
- 3:28Speaker 1: evaluating off-label uses of existing drugs for conditions like aging-related diseases.
- 3:33Speaker 1: The team also conducts comprehensive research on the mechanisms behind
- 3:37Speaker 1: these conditions, ensuring that any new treatments are both effective
- 3:42Speaker 1: and safe.
- 3:43Speaker 2: That's quite intense. And I imagine the commercial and ethical
- 3:47Speaker 2: considerations must be a balancing act. Can you elaborate on
- 3:50Speaker 2: how Old navigated those challenges?
- 3:53Speaker 1: Certainly. At Novartis, he had to balance the need for
- 3:56Speaker 1: commercial success with the ethical standards of drug development. This
- 4:00Speaker 1: meant ensuring that all research was conducted transparently, with rigorous
- 4:04Speaker 1: safety and efficacy standards in place. At the same time,
- 4:09Speaker 1: he focused on areas where unmet needs were greatest, like sarcopenia,
- 4:14Speaker 1: to make a significant difference in patient outcomes.
- 4:16Speaker 2: And that really sets a tone for how the industry
- 4:19Speaker 2: as a whole can approach these complex issues. Lloyd J.
- 4:23Speaker 2: Old's journey is a powerful example of how multidisciplinary collaboration
- 4:27Speaker 2: and a relentless focus on innovation can lead to groundbreaking
- 4:31Speaker 2: achievements in medical research.
- 4:33Speaker 1: Let's dive into the intricate process of drug discovery. It's
- 4:37Speaker 1: not just about finding the next blockbuster, but about identifying
- 4:40Speaker 1: the right indications and choosing between small molecules and biologics.
- 4:46Speaker 1: Think about the early step scientists like Lloyd J. Old
- 4:49Speaker 1: are essentially detectives, gathering clues to identify which diseases have
- 4:55Speaker 1: unmet needs.
- 4:56Speaker 2: Exactly. And once they have pinpointed an indication, they have
- 5:00Speaker 2: a spectrum of tools at their disposal. It's like deciding
- 5:03Speaker 2: between a traditional pharmaceutical and a cutting-edge technology. For instance,
- 5:09Speaker 2: small molecules are like the tried and true penicillin. You
- 5:12Speaker 2: know exactly what you are getting. Biologics, on the other hand,
- 5:16Speaker 2: are more like the advanced CRISPR techniques. They are complex
- 5:19Speaker 2: but potent.
- 5:20Speaker 1: Right, and that's the crucial nuance here. Small molecules are
- 5:24Speaker 1: usually faster to develop and have a lower risk, whereas
- 5:27Speaker 1: biologics offer more precise treatments but come with higher costs
- 5:31Speaker 1: and longer development times. Take, for example, sarcopenia. a condition
- 5:37Speaker 1: where the muscles start to weaken as we age. The
- 5:39Speaker 1: research team would have to weigh the pros and cons
- 5:43Speaker 1: of each approach.
- 5:44Speaker 2: That's wild when you look at the raw numbers. At Novartis,
- 5:48Speaker 2: they screened over 300,000 small molecules, and only a fraction
- 5:52Speaker 2: ever make it to clinical trials. Each one undergoes a
- 5:56Speaker 2: series of rigorous tests to ensure it's both safe and effective.
- 6:00Speaker 2: It's like running a marathon with multiple hurdles. Only these
- 6:04Speaker 2: hurdles are safety, efficacy, and patentability.
- 6:08Speaker 1: Yes, and that leads us to the validation phase. The
- 6:11Speaker 1: clinical trials are where the rubber meets the road. From
- 6:14Speaker 1: phase 1 to 3, each step is meticulously designed to
- 6:17Speaker 1: ensure the drug candidate can be safely given to humans.
- 6:22Speaker 1: Imagine a drug going through a series of tests like
- 6:25Speaker 1: a game of scientific charades. Each step refines the drug,
- 6:29Speaker 1: making sure it's the best possible option for the patient. Exactly.
- 6:33Speaker 2: Which brings up an interesting contradiction. While the clinical trials
- 6:37Speaker 2: aim for the best outcomes, TREs often a conflict between
- 6:41Speaker 2: speed and thoroughness. The regulatory bodies, like the FDA, want
- 6:45Speaker 2: to ensure the safety of every drug, while companies want
- 6:48Speaker 2: to bring new treatments to market as quickly as possible.
- 6:51Speaker 2: It's like a dance, where everyone is trying to keep
- 6:54Speaker 2: their balance while moving forward.
- 6:56Speaker 1: And that's where the stakeholders come in. From the scientists
- 7:00Speaker 1: who innovate, to the healthcare providers who administer the treatments
- 7:04Speaker 1: and the patients who benefit or are affected. It's a
- 7:08Speaker 1: complex ecosystem that requires delicate coordination. Take, for instance, the
- 7:13Speaker 1: New Indications Discovery Unit NICD. It's an effort to bring
- 7:18Speaker 1: in various perspectives, ensuring that all voices are heard in
- 7:22Speaker 1: the drugs development.
- 7:23Speaker 2: Right. And it's not just about the science. The economic
- 7:27Speaker 2: and ethical considerations play a huge role, too. How do
- 7:31Speaker 2: you balance the need for innovation with the costs of development?
- 7:35Speaker 2: And how do you ensure that the benefits don't go
- 7:37Speaker 2: to just the wealthy, leaving everyone else behind?
- 7:40Speaker 1: Those are all excellent points. As we continue to explore
- 7:44Speaker 1: drug discovery, it's clear that it's not just about the science,
- 7:48Speaker 1: it's about the full spectrum of stakeholders and how they
- 7:51Speaker 1: can work together to ensure that medical advancements are accessible
- 7:55Speaker 1: and effective. So, let's dive into the heart of the
- 7:57Speaker 1: matter here. We know that drug discovery is a complex
- 8:01Speaker 1: landscape where risk and reward, commercial success, and ethical considerations
- 8:06Speaker 1: often clash. How do these dynamics play out in the
- 8:09Speaker 1: real world?
- 8:10Speaker 2: Absolutely, Rachel. Let's start with risk versus reward. When you
- 8:14Speaker 2: have a drug with the potential to save lives, it's clear-cut.
- 8:18Speaker 2: But when the stakes are high, like in Lloyd Old's
- 8:21Speaker 2: work with sarcopenia, the risk becomes a major factor. He
- 8:25Speaker 2: and his team at ENICD had to balance the potential
- 8:28Speaker 2: for a groundbreaking treatment with the financial and ethical costs
- 8:32Speaker 2: of bringing it to market.
- 8:34Speaker 1: Exactly. That's the crucial nuance here. Take the development of
- 8:38Speaker 1: a drug for a disease like sarcopenia, where the condition
- 8:41Speaker 1: affects millions of people worldwide. How do you weigh the
- 8:44Speaker 1: risk of clinical failures against the potential to significantly improve
- 8:48Speaker 1: the quality of life for the elderly? It's a tough call,
- 8:52Speaker 1: and the stakes are enormous.
- 8:53Speaker 2: Right. And it's not just about the financial risk. Ethical
- 8:57Speaker 2: considerations come into play, too. Lloyd Old faced the dilemma
- 9:00Speaker 2: of ensuring that ethical standards were kept high, especially when
- 9:04Speaker 2: targeting vulnerable populations. Take, for example, the need to respect
- 9:08Speaker 2: patient privacy while also pushing the limits of what's possible
- 9:11Speaker 2: in treatment innovation.
- 9:12Speaker 1: That's wild when you look at the raw numbers. According
- 9:15Speaker 1: to research, the three-year mortality rate for frail elderly patients
- 9:20Speaker 1: is about 90%. This underscores the urgency of solving these
- 9:25Speaker 1: medical challenges. But when you add in the time and
- 9:28Speaker 1: cost factors, you get a complex equation where no single
- 9:33Speaker 1: solution works for everyone.
- 9:34Speaker 2: Exactly, which brings up an interesting contradiction. Lloyd Old's work
- 9:39Speaker 2: at Novartis often involved navigating the tension between patent laws
- 9:42Speaker 2: and drug accessibility. On one hand, patents are necessary to
- 9:46Speaker 2: protect the investment and drive innovation. On the other hand,
- 9:50Speaker 2: these same patents can limit access to life-saving treatments, particularly
- 9:54Speaker 2: in less affluent regions.
- 9:56Speaker 1: Right. The balance between commercial goals and ethical responsibilities is
- 10:01Speaker 1: a delicate one. Old's contributions were not just about the science,
- 10:05Speaker 1: but about ensuring that the innovations are both effective and fair.
- 10:09Speaker 1: He and his team had to continually evaluate how commercial
- 10:13Speaker 1: pressures could influence their research. And it's a tightrope walk.
- 10:16Speaker 2: Absolutely. Take the New Indications Discovery Unit at Novartis. It's
- 10:21Speaker 2: a beacon for multifaceted research, but it also faces the
- 10:25Speaker 2: commercial realities of drug development. How do you reconcile the
- 10:29Speaker 2: need for robust intellectual property with the goal of making
- 10:32Speaker 2: treatments accessible to all? It's a question that challenges not
- 10:36Speaker 2: just Old's team, but the entire industry.
- 10:38Speaker 1: That's a poignant point, and it leads us to the
- 10:41Speaker 1: broader debate about patent law and access. How can we
- 10:45Speaker 1: create a system that both incentivizes innovation and ensures that
- 10:51Speaker 1: the benefits reach those in need? It's a conversation that
- 10:54Speaker 1: requires collaboration between stakeholders, including patients, healthcare providers, and policymakers.
- 11:02Speaker 2: True. It's about creating a framework that supports ethical practices
- 11:06Speaker 2: and equitable access. For instance, Old and his team worked
- 11:10Speaker 2: on various pathways to innovation. recognizing that one size fits
- 11:14Speaker 2: all solutions are rarely effective. They looked at how small
- 11:18Speaker 2: molecules and biologics could be integrated, understanding that sometimes biologics
- 11:23Speaker 2: offer more specialized therapies, while small molecules provide broader application.
- 11:29Speaker 1: And this is where the rubber hits the road, isn't it?
- 11:33Speaker 1: The path from discovery to application is fraught with both
- 11:36Speaker 1: risk and reward, and the ethical considerations are just as critical.
- 11:41Speaker 1: Lloyd Old's work at Novartis is a testament to navigating
- 11:45Speaker 1: these complexities with integrity and insight. It's not just about
- 11:50Speaker 1: the science, it's about making sure that the outcomes benefit
- 11:54Speaker 1: the broader community. Lloyd J. Old often quoted, we need
- 11:57Speaker 1: to make the most needed medicines and find out what
- 12:00Speaker 1: we are not doing that we should be doing. This
- 12:03Speaker 1: sentiment encapsulates the heart of unmet medical needs and the
- 12:06Speaker 1: ongoing quest to address them through advanced technologies.
- 12:10Speaker 2: Absolutely, Rachel. It's vital to look beyond the surface and
- 12:13Speaker 2: delve into the unmet needs especially in aging research. Take sarcopenia,
- 12:18Speaker 2: for instance. Old's peers have emphasized the critical gap in
- 12:21Speaker 2: treatment options for loss of muscle mass in the elderly.
- 12:24Speaker 1: Right, and that's the crucial nuance here. Sarcopenia isn't just
- 12:28Speaker 1: a medical condition. It's a significant factor in the quality
- 12:31Speaker 1: of life for aging populations. Old and his team at
- 12:34Speaker 1: ISCD have been pivotal in bringing this issue to light.
- 12:37Speaker 2: Exactly, which brings up an interesting contradiction. While advances in
- 12:42Speaker 2: aging research are promising, Therese still a lack of consensus
- 12:46Speaker 2: on how to effectively address these issues at scale. This
- 12:49Speaker 2: isn't just a healthcare challenge, but a broader societal issue. True.
- 12:53Speaker 1: And it's not just about treatment. The future outlook for
- 12:56Speaker 1: aging research also hinges on collaborative innovation. Old frequently mentioned
- 13:01Speaker 1: the importance of multidisciplinary collaborations. How can we foster a
- 13:05Speaker 1: more integrated approach?
- 13:07Speaker 2: That's where advanced technologies come in. The integration of IoT
- 13:11Speaker 2: and wearable devices, for example, allows us to monitor patient
- 13:15Speaker 2: data in real time. This can lead to personalized treatment
- 13:19Speaker 2: strategies that are more effective and efficient.
- 13:22Speaker 1: Exactly. These technologies can also help in early detection, ultimately
- 13:27Speaker 1: reducing the burden on healthcare systems. Speaking of which, what
- 13:31Speaker 1: about regulatory frameworks? How do they support rapid innovation in
- 13:36Speaker 1: unmet medical needs?
- 13:37Speaker 2: That's a critical point. Regulatory bodies like the FDA and
- 13:41Speaker 2: EMA need to strike a balance between expedited approval processes
- 13:45Speaker 2: and thorough validation. This ensures that new treatments are both
- 13:49Speaker 2: safe and effective, but also accessible to those who need them. Right.
- 13:53Speaker 1: And this brings us to the next challenge. How can
- 13:56Speaker 1: we ensure that patient-centric approaches are integrated into drug development pipelines?
- 14:02Speaker 1: Old believed strongly in involving patients in the research process.
- 14:07Speaker 2: Absolutely. Patient involvement can drive innovation in ways that clinical
- 14:11Speaker 2: data alone can't. It ensures that the needs of the
- 14:14Speaker 2: community are at the forefront, leading to more effective solutions.
- 14:18Speaker 2: But the question remains, how can we institutionalize such practices?
- 14:22Speaker 1: That's a good segue into the future outlook. Looking ahead,
- 14:26Speaker 1: the integration of advanced technologies with collaborative innovation will be key.
- 14:32Speaker 1: We need to not only discover new drugs, but also
- 14:36Speaker 1: ensure they are applied to real-world challenges effectively.
- 14:39Speaker 2: Exactly. The future of drug development is indeed transformative, but
- 14:44Speaker 2: it requires sustained effort and a commitment to collaboration and
- 14:48Speaker 2: patient centricity. How do we make these innovations accessible on
- 14:53Speaker 2: a broader scale?
- 14:54Speaker 1: Well, it's clear that the path ahead is complex, but
- 14:57Speaker 1: the potential outcomes are profound. By continuing to explore these
- 15:02Speaker 1: unmet needs and leveraging advanced technologies, we can make significant
- 15:06Speaker 1: strides in improving the quality of life for the elderly
- 15:10Speaker 1: and beyond. As we wrap this up, Thomas, what do
- 15:13Speaker 1: you think is the most critical takeaway from our exploration
- 15:17Speaker 1: of drug development and innovation today?
- 15:19Speaker 2: Great question, Rachel. I think the key is recognizing that
- 15:23Speaker 2: drug development isn't just about finding the next wonder drug.
- 15:27Speaker 2: It's about a holistic, patient-centric approach that balances scientific discovery
- 15:31Speaker 2: with practical considerations. It's a marathon, not a sprint.
- 15:35Speaker 1: Exactly. And this holistic approach includes everything from understanding patient
- 15:40Speaker 1: needs at the very beginning to the complex regulatory environment
- 15:45Speaker 1: that ensures safety and efficacy. We have seen how unmet
- 15:49Speaker 1: medical needs, especially in aging, require a multifaceted solution, one
- 15:54Speaker 1: that involves not just scientists and regulators, but also healthcare providers, and,
- 16:00Speaker 1: most importantly... the patients themselves.
- 16:02Speaker 2: That's spot on. Take, for example, the issue of sarcopenia.
- 16:07Speaker 2: While we can develop a new drug, making sure it's
- 16:09Speaker 2: accessible and effective in real-world settings, like nursing homes, is
- 16:14Speaker 2: just as crucial. It's about understanding the lived experience of
- 16:17Speaker 2: aging and what truly matters to the elderly population.
- 16:20Speaker 1: Right. And let's not forget the ongoing debate over small
- 16:24Speaker 1: molecules versus biologics. Each has its strengths, but also significant challenges.
- 16:30Speaker 1: For instance, Biologics might offer tailored treatments, but could be
- 16:34Speaker 1: more expensive and harder to produce. Small molecules, on the
- 16:39Speaker 1: other hand, might be cheaper but less specific. Finding the
- 16:43Speaker 1: right balance is key.
- 16:44Speaker 2: Speaking of balance, the risk-reward dynamic is always fascinating. We
- 16:49Speaker 2: can't just prioritize profit over patient health, but at the
- 16:53Speaker 2: same time, we need to be realistic about the costs
- 16:56Speaker 2: and feasibility of bringing a new drug to market. This
- 17:00Speaker 2: ethical dilemma is at the heart of what we are discussing.
- 17:03Speaker 1: Absolutely. And that's where innovative technologies like IoT and wearable
- 17:08Speaker 1: devices come in. They can help us gather data in
- 17:11Speaker 1: real time, making the development and application of drugs more
- 17:15Speaker 1: efficient and patient, friendly.
- 17:17Speaker 2: Exactly think of it as a feedback loop where the
- 17:20Speaker 2: data gathered can inform both the development process and the
- 17:24Speaker 2: application of the drug. This kind of innovation not only
- 17:28Speaker 2: improves patient outcomes, but also reduces the burden on healthcare systems.
- 17:32Speaker 1: And let's not lose sight of the future outlook. With
- 17:35Speaker 1: aging populations growing globally, the focus on therapeutics for age-related
- 17:39Speaker 1: diseases will only become more critical. We need to continue
- 17:43Speaker 1: pushing the boundaries of what's possible in drug development, but
- 17:47Speaker 1: we also need to ensure that these innovations are sustainable
- 17:50Speaker 1: and equitable.
- 17:51Speaker 2: True. The future is promising but also challenges us to
- 17:54Speaker 2: stay committed to this holistic, patient-centric approach. It's about finding
- 17:59Speaker 2: that sweet spot where cutting-edge science meets practical needs, and
- 18:03Speaker 2: that's the essence of what we are fighting for.
- 18:06Speaker 1: Well said, Thomas. As we conclude this episode, let's remember
- 18:10Speaker 1: that the journey of drug development is complex, but that
- 18:14Speaker 1: doesn't mean we should give up. It means we need
- 18:16Speaker 1: to stay engaged, continue learning. and work together to make
- 18:20Speaker 1: meaningful improvements in medical innovation and patient outcomes.
- 18:25Speaker 2: Absolutely, Rachel. It's an ongoing journey, but one that's worth
- 18:29Speaker 2: every step. Thanks for the insightful discussion.
- 18:32Speaker 1: That brings us to the end of today's episode. Thank
- 18:34Speaker 1: you so much for spending part of your day with me.
- 18:37Speaker 1: If you found this episode's tips helpful and want to
- 18:40Speaker 1: make sure you don't miss the next conversation, please take
- 18:42Speaker 1: a quick second to hit that subscribe or follow button
- 18:46Speaker 1: on whatever platform you are listening on. It's a completely
- 18:49Speaker 1: free way to support the show and helps more people
- 18:51Speaker 1: find us. This podcast is independently produced, so if you
- 18:55Speaker 1: are ever in a position where you would like to
- 18:57Speaker 1: help keep it running, we do accept small donations. You
- 19:01Speaker 1: can find a link right in the episode description below
- 19:04Speaker 1: to buy us a coffee or contribute what you can.
- 19:07Speaker 1: Every bit genuinely helps. Take care of yourself, stay balanced,
- 19:12Speaker 1: and we will talk again soon.